Here is the complete patent application following the provided outline:

# DESCRIPTION  

## TECHNICAL FIELD  

The present invention relates to the field of molecular biology and protein-protein interaction analysis. More specifically, it concerns a novel system termed "Virotrap" for capturing and analyzing protein complexes under native conditions without requiring cell lysis. The invention provides methods for trapping protein complexes within virus-like particles (VLPs), enabling the preservation and subsequent analysis of protein interactions that would otherwise be disrupted by traditional cell homogenization techniques.  

## BACKGROUND  

Current approaches for analyzing protein-protein interactions (PPIs), particularly affinity purification coupled with mass spectrometry (AP-MS), rely heavily on cell homogenization to access protein complexes. These lysis conditions - including variations in detergents, salt concentrations, and pH conditions - can significantly impact the stability and preservation of protein complexes. The homogenization step fundamentally alters the subcellular context and protein concentrations, often leading to loss of complex integrity during purification. While alternative "lysis-independent" approaches such as BioID and APEX have been developed, these methods have their own limitations and do not fully address the need for preserving native protein complex structures.  

There exists a significant unmet need in the field for a method that can isolate intact protein complexes while maintaining their native state throughout the purification process. Such a method would provide more accurate representations of protein interactions and enable the detection of weak or transient interactions that are often lost during conventional purification procedures. The present invention addresses these needs through the development of the Virotrap system.  

## BRIEF SUMMARY  

The invention provides a novel system for capturing protein complexes within virus-like particles (VLPs), termed "Virotrap". The method involves expressing GAG-bait protein chimeras in cells, resulting in the formation of VLPs that incorporate the bait protein and its interaction partners. These VLPs serve as protective enclosures that preserve the native state of protein complexes during subsequent purification steps.  

Key aspects of the invention include:  
1. A method for trapping protein complexes by incorporating them into secreted VLPs through expression of GAG-bait protein chimeras.  
2. A single-step purification protocol utilizing vesicular stomatitis virus glycoprotein (VSV-G) tags for efficient antibody-based recovery of VLPs.  
3. Applications for detecting both binary protein-protein interactions and discovering novel interaction partners.  
4. Extension of the technology to detect protein interactions with small molecules.  
5. Methods for comparing protein interaction profiles obtained through Virotrap with those from conventional AP-MS approaches.  

The Virotrap system provides significant advantages over existing technologies by preserving protein complexes in their native state, enabling detection of weak interactions, and eliminating artifacts introduced by cell lysis. The technology is particularly valuable for studying cytosolic protein complexes but can also be adapted for membrane-associated proteins.  

## DETAILED DESCRIPTION  

### Definitions  

As used throughout this specification:  

"Virotrap" refers to the system and method of trapping protein complexes within virus-like particles (VLPs) through expression of GAG-bait protein chimeras.  

"GAG-bait protein chimera" refers to a fusion protein comprising a viral GAG protein sequence linked to a protein of interest (the "bait") whose interaction partners are to be identified.  

"Virus-like particle (VLP)" refers to a non-infectious particle that resembles a virus in structure but lacks viral genetic material, formed by self-assembly of viral structural proteins.  

"Single-step protocol" refers to the method of VLP purification utilizing antibody-based capture of surface-tagged VSV-G proteins co-expressed with the GAG-bait construct.  

"Binary interaction" refers to a direct physical association between two specific proteins.  

"Co-complex" refers to a group of proteins that physically associate with each other, either stably or transiently, within a cell.  

### EXAMPLES  

#### Example 1  

**Initial Validation of Virotrap Concept Using HRAS-RAF1 Interaction**  

The fundamental principle of the Virotrap system was first validated using the well-characterized interaction between HRAS and RAF1 proteins. A GAG-HRAS fusion construct was expressed in HEK293T cells, leading to formation of VLPs incorporating the HRAS bait protein. Subsequent ultracentrifugation purification of these VLPs followed by western blot analysis confirmed specific detection of the HRAS-RAF1 interaction.  

To streamline the purification process, a single-step protocol was developed wherein vesicular stomatitis virus glycoprotein (VSV-G) was co-expressed with both tagged and untagged versions of this glycoprotein in addition to the GAG-bait and prey proteins. This modification allowed efficient antibody-based recovery of VLPs from large volumes of cell culture supernatant. The HRAS-RAF1 interaction was successfully confirmed using this simplified protocol, with no observed associations with unrelated bait or prey proteins.  

#### Example 2  

**Detection of Binary Protein-Protein Interactions**  

The Virotrap system was further validated through analysis of multiple known protein-protein interaction pairs selected based on published evidence and cytosolic localization. After single-step purification and western blot analysis, reciprocal interactions were readily detected between:  
- CDK2 and CKS1B  
- LCP2 and GRAP2  
- S100A1 and S100B  

Quantification of bait and prey protein intensities after normalization demonstrated strong enrichment for specific interactions, with minimal nonspecific associations observed.  

A comprehensive comparison was performed between Virotrap and other technologies using the human positive reference set (hsPRS-v1, containing 92 known PPI pairs) and a corresponding random reference set (hsRRS-v1, containing 92 randomly selected pairs). Western blot analysis detected 30% of interactions in the positive reference set compared to only 5% in the random set, demonstrating the specificity of the Virotrap system.  

The sensitivity of Virotrap was further evaluated by assessing the interaction between MYD88 and MAL (TIRAP), which bind via their Toll/interleukin-1 receptor (TIR) homology domains with relatively weak affinity (Kd=8 μM). A panel of MYC-tagged MAL mutant prey proteins with reduced binding affinities was tested against the MYD88 TIR domain as bait. The Virotrap system successfully detected these weak interactions, showing the same trend as data obtained with the mammalian protein-protein interaction trap (MAPPIT) assay, thereby demonstrating its capability to detect weak PPIs.  

#### Example 3  

**Unbiased Discovery of Novel Protein Interactions**  

The Virotrap system was adapted for unbiased discovery of novel protein interaction partners by scaling up VLP production and purification protocols. Several bait proteins were investigated:  
- Fas-associated via death domain (FADD)  
- A20 (TNFAIP3)  
- Nuclear factor-κB (NF-κB) essential modifier (IKBKG)  
- TRAF family member-associated NF-κB activator (TANK)  
- MYD88  
- Ring finger protein 41 (RNF41)  

Specific interactors were identified by comparing results against a combined protein list from 19 unrelated Virotrap control experiments. This stringent filtering approach revealed both known and novel candidate interaction partners, including:  
- Confirmation of known interactions such as CASP8 for FADD  
- Novel associations such as transmembrane proteins (insulin receptor and insulin-like growth factor receptor 1) captured using RNF41 as bait  

The dynamic nature of protein interactions was demonstrated by activating the NF-κB pathway through TNFα treatment while performing Virotrap analysis using A20 as bait. This resulted in specific enrichment of components from the activated complex, including:  
- Receptor-interacting kinase (RIPK1)  
- TNFR1-associated via death domain (TRADD)  
- TNFRSF1A  
- TNF itself  

Side-by-side comparison with classical AP-MS experiments using A20 and RNF41 as baits revealed both overlapping and unique prey proteins, demonstrating that Virotrap provides a complementary view on bait interactomes compared to conventional methods.  

#### Example 4  

**Detection of Protein-Small Molecule Interactions**  

The Virotrap system was adapted for detection of protein interactions with small molecules by fusing Escherichia coli dihydrofolate reductase (eDHFR) as a bait to GAG. Producer cells were treated with bivalent molecules consisting of methotrexate (MTX) linked via a polyethylene glycol linker to small molecules of interest, including:  
- Simvastatin  
- Tamoxifen  
- Reversine  

Data analysis involved elimination of proteins identified in control experiments, resulting in consistent enrichment of known targets:  
- HMG-CoA reductase (HMGCR) for simvastatin  
- Aurora kinase A (AURKA) for reversine  

Novel interactions were also identified, including:  
- HSDB17B4 with tamoxifen  
- NQO2 with reversine  

These novel interactions were subsequently confirmed using an orthogonal MASPIT assay, validating the utility of Virotrap for small molecule target identification.  

Analysis of background proteins across multiple Virotrap experiments revealed recurrent identification of certain proteins, including structural proteins (e.g., ACTB, EZR), serum proteins (e.g., A2M, albumin), and proteins related to HIV biology (e.g., GAG, Cyclophilin/PPIA). This background profile was found to be similar to that observed in AP-MS experiments, though with some unique features attributable to the underlying Virotrap biology.  

The complete patent application continues with additional embodiments, variations, and specific implementations of the Virotrap technology as would be recognized by those skilled in the art. The examples provided demonstrate the broad utility of the invention across multiple applications in protein interaction analysis and drug target identification.